In addition, ASCT may normalize abnormal bone resorption in MM patients by decreasing the RANKL/OPG ratio, while bone formation took longer to normalize.26 In a prospective phase 2 study of 33 patients treated with daratumumab, dickkopf-1 and C-C motif ligand-3 decreased significantly, while the levels of osteocalcin, BALP and PINP increased. The gene discussed is TNFRSF11B; the disease is Miyoshi myopathy.